In order to succeed, biotech, drug, and device companies must publish their results in peer-reviewed journals in an effort to add value to promote and commercialize their technologies. The drivers of this exercise include reimbursement, credibility, commercialization and valuations. If you’re not publishing, you’re missing out on valuable opportunities to improve the chances for your company to succeed.

In this interactive program, you will learn the how, why and when of a successful publication strategy. Experts in the field will be joined by professionals who have effectively implemented the process. You will learn from their successes and failures.

Topics to be covered:

  • When, where and what to publish
  • Timing of publications throughout the product development cycle
  • Article types to consider, and why; look at both home runs and base hits
  • How peer-reviewed publications support reimbursement strategy
  • Developing a roadmap to maximize publication objectives
  • PR and your publication program

The program will include case examples and a sample roadmap for success.

Speakers:
Joel Batts | Partner, Telos Partners, LLC read bio»

Agenda:
3:30 PM | Registration and Networking
4:00 PM | Presentation
4:30 PM | Q&A
5:00 PM | Panel Discussion
5:45 PM | Q&A
6:00 PM | Food and Networking
7:00 PM | Program Close

Fees:
$25 | General Public
$15 | Student/Academic
$45 | At the door

Location:
JLABS @ Toronto
661 University Ave, Suite 1300
Toronto, Ontario

Speakers’ Biographies:

Joel Batts, MA | Partner at Telos Partners, LLC
Joel is a medical device industry veteran, with 20 years of leadership experience developing scientific and regulatory strategies for start-ups to large cap companies. He has delivered >$100 million return on investment by delivering FDA approvals for Class II and Class III devices in the musculoskeletal and wound care spaces. He has published and presented the results of pre-clinical and clinical science in journals such as American Journal of Sports Medicine, American Journal of Orthopaedics, and venues such as the American College of Foot and Ankle Surgeons. In 2010, he led a business development team in the application of a novel biologic material to osteoporotic patients for reducing the incidence of hip fractures. After conducting early-phase trials and developing the scientific and regulatory, the team sold the technology for $30 million. He has also overseen key areas of investment and integration for four major acquisitions. Outside of Telos Partners, Joel is part of a LifeNet International, a non-profit that is transforming healthcare in African communities. Joel earned a BS in exercise science from the University of Florida and an MA in bioethics and health policy from Loyola University Chicago.

Back to all